Literature DB >> 23573397

Plasmapheresis-induced hypercalcaemia.

Anas-Alwogud Abdelmogheth1, Islam El-Baroudy, Saif Al-Yaaruby.   

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that can cause total motor paralysis in severe cases. Reports of hypercalcaemia in patients with GBS are rare. Plasmapheresis, an extracorporeal blood purification procedure for the removal of large molecular weight substances, is a well-established therapy for ventilated GBS patients. Although it has been observed in a few reported cases, theoretically, hypercalcaemia is not described as a plasmapheresis-related problem unless there is an underlying cause. We present a rare case of an 8-year-old child presenting with headache, diplopia, and squint, followed by disturbed conscious levels and paralysis. He was treated with both intravenous immunoglobulin and plasmapheresis, with a favourable outcome. We made a laboratory observation of hypercalcaemia which was associated with the plasmapheresis therapy without any related underlying cause. This raises the need for similar observations and the gathering of other possible acceptable explanations.

Entities:  

Keywords:  Case report; Guillain-Barré syndrome; Hypercalcemia; Oman; Plasmapheresis

Year:  2013        PMID: 23573397      PMCID: PMC3616782     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  9 in total

Review 1.  The management of primary hyperparathyroidism.

Authors:  M Davies; W D Fraser; D J Hosking
Journal:  Clin Endocrinol (Oxf)       Date:  2002-08       Impact factor: 3.478

Review 2.  Guillain-Barré syndrome.

Authors:  Nobuhiro Yuki; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

3.  Therapeutic plasma exchange: core curriculum 2008.

Authors:  Andre A Kaplan
Journal:  Am J Kidney Dis       Date:  2008-06-17       Impact factor: 8.860

4.  Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate.

Authors:  J M Meythaler; A B Korkor; T Nanda; N A Kumar; M Fallon
Journal:  Arch Intern Med       Date:  1986-08

Review 5.  Clinical review: Rare causes of hypercalcemia.

Authors:  Thomas P Jacobs; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

Review 6.  Guillain-Barré syndrome in childhood.

Authors:  Monique M Ryan
Journal:  J Paediatr Child Health       Date:  2005 May-Jun       Impact factor: 1.954

7.  Primary hyperparathyroidism in pediatric patients.

Authors:  Josh Kollars; Abdalla E Zarroug; Jon van Heerden; Aida Lteif; Penny Stavlo; Luis Suarez; Christopher Moir; Michael Ishitani; David Rodeberg
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

8.  Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.

Authors:  W F Haupt; F Rosenow; C van der Ven; H Borberg; G Pawlik
Journal:  J Neurol Sci       Date:  1996-05       Impact factor: 3.181

9.  Changes in calcium distribution during therapeutic plasmapheresis.

Authors:  W H Roberts; R E Domen; M I Walters
Journal:  Arch Pathol Lab Med       Date:  1984-11       Impact factor: 5.534

  9 in total
  1 in total

Review 1.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.